ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy
Global Medical Genetics · 01.09.2023 · 10 (03) · 164-171
DOI: 10.1055/s-0043-1771001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Medical Genetics, erschienen am 01.09.2023. Verfasst von Fatemeh Fakhr und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deputies of research of Isfahan University of Medical Sciences.
Abstract (Originalsprache)
Interferon (IFN)-β is the first-line disease management choice in multiple sclerosis (MS) with profound effects; however, in up to 50% of patients, clinical response does not occur. Ascertaining the responding state, need a long-term clinical follow-up, and this may lead to delay in use of other effective medications. IFN-induced cascade and its regulation is considered to play a major role in MS. Adenosine deaminase, RNA-specific (ADAR) dysregulation is important to IFN signaling pathway as an activity suppressor. Hence, we investigated the expression of ADAR and its single nucleotide variants of rs2229857 association with response to IFN-β in relapsing-remitting MS patients. mRNA levels and genotyping of rs2229857 in 167 MS patients were investigated via SYBR Green real-time (RT)-quantitative polymerase chain reaction and high-resolution melting RT PCR, respectively. The allele-A in rs2229857 and higher expression of ADAR were associated with poor response to IFN-β. Two response groups were significantly different in terms of annualized relapse rate, first symptoms, first extended disability status scale (EDSS), current EDSS, and the MS severity score. According to this study's findings, assessment of transcript levels and also variants in ADAR may be useful in identifying patients' response to IFN-β before starting treatment. Further investigations are needed to determine the potency of ADAR to be a predictive biomarker in drug responsiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
- Department of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Förderung
- Deputies of research of Isfahan University of Medical Sciences
Zitieren
APA
Fakhr, F., Shaygannejad, V., Khorrami, M., Saberi, L., Mirmosayyeb, O., Sadeghi, E., & Kheirollahi, M. (2023). ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy. Global Medical Genetics, 10(03), 164-171. https://doi.org/10.1055/s-0043-1771001
Vancouver
Fakhr F, Shaygannejad V, Khorrami M, Saberi L, Mirmosayyeb O, Sadeghi E, et al. ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy. Global Medical Genetics. 2023;10(03):164-171. doi:10.1055/s-0043-1771001
BibTeX
@article{Fakhr2023,
author = {Fakhr, Fatemeh and Shaygannejad, Vahid and Khorrami, Mehdi and Saberi, Leila and Mirmosayyeb, Omid and Sadeghi, Erfan and Kheirollahi, Majid},
title = {ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy},
journal = {Global Medical Genetics},
year = {2023},
volume = {10},
number = {03},
pages = {164--171},
doi = {10.1055/s-0043-1771001}
}
EUVIMED